Jogeshwari, India

Time filter

Source Type

News Article | November 30, 2016
Site: www.PR.com

Animal Parasiticides Market Anticipated to Grow US$ 13,064.7 Mn by 2026 In this report, Persistence Market Research (PMR) offers a ten year forecast of the global animal parasiticides market between 2016 and 2026. New York, NY, November 30, 2016 --( The prime factors powering the demand for animal parasiticides are increasing awareness about animal healthcare, increasing demand of animal derived food products, growing concern about foodborne diseases and zoonotic diseases, growth in adoption of companion animals and increase in animal healthcare expenditure. However, a growing preference for vegetarian food and diet and a stringent approval process for animal parasiticides coupled with restrictions on the use of parasiticides in food producing animals are the restraints affecting the global animal parasiticides market. A key trend defining the market is that larger players are focused towards enhancing their geographical presence and expanding their customer base by entering into strategic mergers and acquisitions. Furthermore, huge investment from government organizations and private players for research and development activities is also a key trend of global animal parasiticides market. The market is segmented based on product type, animal type, distribution channel and region. Based on product type, the market is sub-segmented into Ectoparasiticides, Endoparasiticides and Endectocides. Among the product type segment, Endoparasiticides segment is expected to exhibit the highest revenue growth over the forecast period. The Endoparasiticides product type segment is expected to register a significant CAGR of 5.9% during the forecast period in terms of value. The Ectoparasiticides segment is projected to exhibit a CAGR of 5.7% over the forecast period in terms of value. The market has also been segmented by animal type into food producing animals and companion animals. The food producing animals segment is expected to be the largest over the forecast period, with the segment witnessing a CAGR of 6.2% during the forecast period. One of the key growth drivers for animal parasiticides market is the growing concern about foodborne and zoonotic diseases. This report assesses trends driving growth of each segment on the regional as well as country level and offers potential takeaways that could prove substantially useful to animal parasiticides manufacturers looking to enter the market. Western Europe market has been estimated to dominate the global animal parasiticides market, accounting for a maximum revenue share of the market by 2016 end. North America is expected to account for over 20.0% revenue share of the global animal parasiticides market by 2016 end. Among the emerging markets, APEJ is estimated to exhibit a significant CAGR of 6.4% over the forecast period, followed by the North America market, due to increasing awareness about animal healthcare and increasing demand for animal derived food products. Some of the key players in the global animal parasiticides market include Sanofi S.A. (Merial), Ceva Sante Animlae, Virbac SA, Vetoquinol S.A., Eli Lilly and Company, Zoetis Inc., Merck & Co Inc., Bayer AG, Boehringer Ingelheim GmbH and Perrigo Co. plc. The report discusses individual strategies followed by these companies in terms of enhancing their product portfolio, creating new marketing techniques, mergers and acquisitions. The ‘Competitive Landscape’ is included to provide report audiences with a dashboard view and company share collectively. Browse Complete Report @ http://www.persistencemarketresearch.com/market-research/animal-parasiticide-market.asp New York, NY, November 30, 2016 --( PR.com )-- The global animal parasiticides market is estimated to register a promising CAGR of 5.9% over the forecast period, owing to numerous factors, about which PMR offers thorough insights and forecasts in this report. The global animal parasiticides market registered a value of US$ 6,976.2 Mn in 2015 and is anticipated to reach a market valuation of US$ 13,064.7 Mn by 2026.The prime factors powering the demand for animal parasiticides are increasing awareness about animal healthcare, increasing demand of animal derived food products, growing concern about foodborne diseases and zoonotic diseases, growth in adoption of companion animals and increase in animal healthcare expenditure. However, a growing preference for vegetarian food and diet and a stringent approval process for animal parasiticides coupled with restrictions on the use of parasiticides in food producing animals are the restraints affecting the global animal parasiticides market.A key trend defining the market is that larger players are focused towards enhancing their geographical presence and expanding their customer base by entering into strategic mergers and acquisitions. Furthermore, huge investment from government organizations and private players for research and development activities is also a key trend of global animal parasiticides market.The market is segmented based on product type, animal type, distribution channel and region. Based on product type, the market is sub-segmented into Ectoparasiticides, Endoparasiticides and Endectocides. Among the product type segment, Endoparasiticides segment is expected to exhibit the highest revenue growth over the forecast period. The Endoparasiticides product type segment is expected to register a significant CAGR of 5.9% during the forecast period in terms of value. The Ectoparasiticides segment is projected to exhibit a CAGR of 5.7% over the forecast period in terms of value.The market has also been segmented by animal type into food producing animals and companion animals. The food producing animals segment is expected to be the largest over the forecast period, with the segment witnessing a CAGR of 6.2% during the forecast period. One of the key growth drivers for animal parasiticides market is the growing concern about foodborne and zoonotic diseases.This report assesses trends driving growth of each segment on the regional as well as country level and offers potential takeaways that could prove substantially useful to animal parasiticides manufacturers looking to enter the market. Western Europe market has been estimated to dominate the global animal parasiticides market, accounting for a maximum revenue share of the market by 2016 end. North America is expected to account for over 20.0% revenue share of the global animal parasiticides market by 2016 end. Among the emerging markets, APEJ is estimated to exhibit a significant CAGR of 6.4% over the forecast period, followed by the North America market, due to increasing awareness about animal healthcare and increasing demand for animal derived food products.Some of the key players in the global animal parasiticides market include Sanofi S.A. (Merial), Ceva Sante Animlae, Virbac SA, Vetoquinol S.A., Eli Lilly and Company, Zoetis Inc., Merck & Co Inc., Bayer AG, Boehringer Ingelheim GmbH and Perrigo Co. plc. The report discusses individual strategies followed by these companies in terms of enhancing their product portfolio, creating new marketing techniques, mergers and acquisitions. The ‘Competitive Landscape’ is included to provide report audiences with a dashboard view and company share collectively.Browse Complete Report @ http://www.persistencemarketresearch.com/market-research/animal-parasiticide-market.asp Click here to view the list of recent Press Releases from Persistence Market Research


News Article | February 17, 2017
Site: www.businesswire.com

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the Cowen and Company 37th Annual Health Care Conference on March 6, 2017, in Boston, Mass. Clint Lewis, Executive Vice President and President, International Operations at Zoetis, will represent the company and respond to questions from analysts. He is scheduled to present at 4:00 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2016, the company generated annual revenue of $4.9 billion with approximately 9,000 employees. For more information, visit www.zoetis.com.


News Article | February 16, 2017
Site: www.businesswire.com

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the fourth quarter and full year 2016 and updated its guidance for the full year 2017. The company reported revenue of $1.3 billion for the fourth quarter of 2016, which was flat compared with the fourth quarter of 2015. Net income for the fourth quarter of 2016 was $154 million, or $0.31 per diluted share compared with $22 million and $0.04 per diluted share in the fourth quarter of 2015. Adjusted net income1 for the fourth quarter of 2016 was $232 million, or $0.47 per diluted share, an increase of 8% and 9%, respectively. Adjusted net income for the fourth quarter of 2016 excludes the net impact of $78 million for purchase accounting adjustments, acquisition-related costs and certain significant items. On an operational2 basis, revenue for the fourth quarter of 2016, excluding the impact of foreign exchange, was flat compared with the fourth quarter of 2015. This performance reflects the impact of fewer calendar days in the quarter, product rationalizations and business changes in certain markets as part of the company’s operational efficiency initiative, and acquisitions. Adjusted net income for the fourth quarter of 2016 increased 13% operationally, excluding the impact of foreign exchange. For full year 2016, the company reported revenue of $4.9 billion, an increase of 3% compared with full year 2015. Net income for full year 2016 was $821 million, or $1.65 per diluted share compared with $339 million and $0.68 per diluted share for full year 2015. Adjusted net income for full year 2016 was $975 million, or $1.96 per diluted share, an increase of 10% and 11%, respectively. Adjusted net income for full year 2016 excludes the net impact of $154 million for purchase accounting adjustments, acquisition-related costs and certain significant items. On an operational basis, revenue for full year 2016 increased 5%, excluding the impact of foreign exchange. This performance reflects the impact of product rationalizations and business changes in certain markets as part of the company’s operational efficiency initiative as well as acquisitions. Adjusted net income for full year 2016 increased 17% operationally, excluding the impact of foreign exchange. “In 2016, we delivered our fourth consecutive year of operational revenue growth and improved profitability since becoming a public company,” said Juan Ramón Alaix, Chief Executive Officer of Zoetis. “Our 5% operational growth for the year was driven by the successful launch of several new products and the strength of our diverse portfolio. We also completed significant initiatives to shape our business for greater efficiency and cash generation, which helped us deliver 17% operational growth in adjusted net income and make investments that will sustain our future growth, innovation and market leadership.” “In the fourth quarter, we delivered another solid quarter of double-digit operational growth in adjusted net income, overcoming the negative impact to revenue of fewer calendar days and business changes related to our operational efficiency initiative,” said Glenn David, Executive Vice President and Chief Financial Officer of Zoetis. “In 2017, we again expect revenue to grow in line with or faster than the market and to deliver double-digit growth in adjusted net income -- fully realizing the benefits of our operational efficiency initiative. Cash flow is expected to grow significantly in 2017, and we will leverage our improved financial position for investments in promising internal and external opportunities and to return excess capital to shareholders.” Zoetis organizes and manages its commercial operations across two regional segments: the United States (U.S.) and International. Within these segments, the company delivers a diverse portfolio of products for livestock and companion animals tailored to local trends and customer needs. In the fourth quarter of 2016: Zoetis continues to drive demand and strengthen its diverse portfolio through new product delivery, lifecycle innovations, strong customer relationships and access to new markets and technologies. The company is focused on enhancing the performance and delivery of its current product lines; expanding product indications across species; pursuing approvals in new geographies; and developing and marketing innovative medicines, treatments and solutions for emerging diseases and unmet customer needs. Zoetis continues to advance animal health through innovations that address market needs or improve veterinarians’ approach to treatment. The company continues to receive approvals for new indications and formulations of key livestock products, as well as expand major products into new geographies. Zoetis' guidance for the full year 2017 has been updated to reflect foreign exchange rates as of late January. The company’s guidance for the full year 2017 includes: Additional guidance on other items such as expenses and tax rate is included in the financial tables and will be discussed on the company's conference call this morning. Zoetis will host a webcast and conference call at 8:30 a.m. (ET) today, during which company executives will review fourth quarter and full year 2016 results, discuss financial guidance and respond to questions from financial analysts. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. A replay of the webcast will be archived and made available on Feb. 16, 2017. Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2016, the company generated annual revenue of $4.9 billion with approximately 9,000 employees. For more information, visit www.zoetis.com. 1 Adjusted net income and its components and adjusted diluted earnings per share (non-GAAP financial measures) are defined as reported net income attributable to Zoetis and reported diluted earnings per share, excluding purchase accounting adjustments, acquisition-related costs and certain significant items. 2 Operational revenue growth (a non-GAAP financial measure) is defined as revenue growth excluding the impact of foreign exchange. Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, future guidance, future operating models, expectations regarding products, future use of cash and dividend payments, tax rate and tax regimes, changes in the tax regimes and laws in other jurisdictions, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis. Use of Non-GAAP Financial Measures: We use non-GAAP financial measures, such as adjusted net income, adjusted diluted earnings per share and operational results (which exclude the impact of foreign exchange), to assess and analyze our results and trends and to make financial and operational decisions. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this press release should not be considered alternatives to measurements required by GAAP, such as net income, operating income, and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliation of non-GAAP financial measures and GAAP financial measures are included in the tables accompanying this press release and are posted on our website at www.zoetis.com. Internet Posting of Information: We routinely post information that may be important to investors in the 'Investors' section of our website at www.zoetis.com, on our Facebook page at http://www.facebook.com/zoetis and on Twitter @zoetis. We encourage investors and potential investors to consult our website regularly and to follow us on Facebook and Twitter for important information about us. The guidance reflects foreign exchange rates as of late January 2017. Reconciliations of 2017 reported guidance to 2017 adjusted guidance follows:


News Article | February 16, 2017
Site: www.businesswire.com

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) a annoncé aujourd’hui que la Commission européenne autorisait la mise sur le marché du médicament Stronghold® Plus (sélamectine/sarolaner), combinaison de parasiticides à application locale qui traite contre les tiques, les puces, la gale auriculaire, les poux et les nématodes gastrointestinaux tout en prévenant de la dirofilariose chez les chats. « L’autorisation de Stronghold Plus permet à Zoetis de proposer aux vétérinaires une nouvelle option topique pour traiter les parasites présentant généralement une menace pour les chats, en appliquant chaque mois à l’animal une dose unique » , a déclaré Dr. Catherine Knupp, vice-présidente en chef et présidente de la recherche et du développement à Zoetis. « Pour la première fois, nous avons combiné notre nouveau parasiticide, le sarolaner, caractérisé par sa versatilité, avec l’agent actif du Stronghold, la sélamectine – combinaison qui a permis au sarolaner d’être autorisé pour la première fois pour une utilisation sur les chats. D’après nous, le sarolaner constitue une base prometteuse pour d’autres gammes de produits et innovations du cycle de vie à venir. Nous nous félicitons des données positives que les études sur le sarolaner et sa combinaison continuent de générer. » M. Domenico Otranto, Professeur en parasitologie de l’université de Bari, en Italie, qui a récemment revu les données du produit Stronghold Plus, a déclaré : « Un certain nombre d’études menées en laboratoire et sur le terrain montrent l’efficacité d’une seule application locale de Stronghold Plus pendant au moins un mois. Les vétérinaires de l’Union européenne disposeront à présent d’une option très efficace pour le traitement et le contrôle de quatre espèces importantes de tiques qui affectent communément les chats, tout en maintenant une efficacité prouvée contre les puces, les vers gastrointestinaux, la dirofilariose, la gale auriculaire et les poux. Au final, les propriétaires d’animaux domestiques tout comme les vétérinaires possèdent désormais un nouvel outil pour améliorer la santé et le bien-être des chats. » Dr. Michael Stegemann, directeur principal de la recherche et du développement vétérinaire à Zoetis, a souligné : « Stronghold Plus a été entièrement découvert et développé par les scientifiques de Zoetis. Ce médicament offre une protection rapide et durable contre les puces et les tiques que l’on trouve souvent sur les chats. L’action combinée du sarolaner et de la sélamectine permet à Stronghold Plus d’éliminer quatre espèces de tiques, tout en prolongeant la durée de la protection contre les puces jusqu’à cinq semaines complètes sans perdre de son efficacité à la fin de la période de traitement – et ce sans sacrifier le niveau de protection contre d’autres parasites internes et externes importants qui affectent les félins. Nous sommes très enthousiastes à l’idée de proposer cette innovation aux vétérinaires de l’Union européenne. » Les substances actives du médicament Stronghold Plus sont la sélamectine et le sarolaner, nouvelle combinaison de parasiticides. La sélamectine a une activité adulticide, ovicide et larvicide contre les puces (Ctenocephalides spp). La sélamectine est également active contre la gale auriculaire, les poux, les nématodes gastrointestinaux et prévient contre la dirofilariose grâce à son efficacité contre la larve Dirofilaria immitis. Le sarolaner est un nouvel acaricide et insecticide de la classe des isoxazolines : il est efficace contre les tiques, les puces et les acariens. Les effets indésirables les plus courants du Stronghold Plus incluent un prurit transitoire et mineur sur le site d’application. Ont été observés dans de rares cas, une alopécie mineure à modérée sur le site d’application, des érythèmes et une salivation excessive. Zoetis est la principale entreprise du secteur de la santé animale. Son objectif est d’aider au mieux ses clients et leur entreprise. Forte de plus de 60 ans d’expérience dans le domaine de la santé animale, Zoetis découvre, développe, fabrique et commercialise des vaccins et des médicaments vétérinaires, des produits diagnostiques et des tests génétiques, en s’appuyant sur toute une gamme de services. Commercialisant ses produits dans plus de 100 pays, Zoetis répond aux besoins des vétérinaires, des éleveurs de bétail et des personnes qui s’occupent d’animaux domestiques. L’entreprise a généré un chiffre d’affaires annuel de 4,8 milliards de dollars US en 2015 et compte environ 9 000 employés. Pour de plus amples informations, rendez-vous sur le site www.zoetis.com. Déclarations prospectives : le présent communiqué de presse contient des déclarations prospectives qui reflètent les perspectives actuelles de Zoetis en accord avec ses perspectives ou plans commerciaux, ses attentes concernant ses produits et autres faits futurs. Les présentes déclarations ne garantissent en rien les résultats ou les actions à venir. Ces déclarations prospectives sont sujettes aux risques et aux incertitudes. Si l’un ou plusieurs de ces risques ou incertitudes se matérialisent, ou si les assomptions sous-jacentes de la direction s’avèrent inexactes, les résultats concrets peuvent différer matériellement de ceux envisagés dans une déclaration prospective. Les déclarations prospectives sont uniquement valides à la date de leur énonciation. Zoetis ne s’engage aucunement à mettre à jour ni à réviser de telles déclarations prospectives, que ce soit suite à de nouvelles informations, évènements futurs ou autres. Une liste et une description plus détaillées des risques, des incertitudes et autres points relatifs sont disponibles dans notre Rapport annuel sur le Formulaire 10-K de l’année fiscale qui s’est terminée au 31 décembre 2015, y compris dans les sections connexes intitulées « Forward-Looking Statements and Factors That May Affect Future Results » (« Déclarations prospectives et facteurs pouvant affecter les résultats futurs ») et « Item 1A. Risk Factors » (« Article 1A. Facteurs de risques »), consultables dans nos Rapports trimestriels sur le Formulaire 10-Q et dans nos Rapports en cours sur le Formulaire 8-K. Ces dossiers comme ceux à venir sont disponibles en ligne à www.sec.gov, www.zoetis.com, ou sur demande auprès de Zoetis.


News Article | February 15, 2017
Site: www.businesswire.com

PARSIPPANY, N.J.--(BUSINESS WIRE)--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a second quarter 2017 dividend payable to holders of the company’s common stock of $0.105 per share. The dividend is to be paid on Thursday, June 1, 2017, to holders of record on Thursday, April 6, 2017. Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2015, the company generated annual revenue of $4.8 billion with approximately 9,000 employees. For more information, visit www.zoetis.com. Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, future guidance, future operating models, expectations regarding products, future use of cash and dividend payments, tax rate and tax regimes, changes in the tax regimes and laws in other jurisdictions, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.


News Article | February 15, 2017
Site: www.businesswire.com

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the company a license for Stronghold® Plus (selamectin/sarolaner), a topical combination of parasiticides that treats ticks, fleas, ear mites, lice and gastrointestinal nematodes and prevents heartworm disease in cats. Veterinarians across the European Union now have a treatment choice that leverages the benefits of sarolaner, a new innovation in the class of isoxazolines, without sacrificing the broad spectrum protection, safety or ease of use they expect. ”The approval of Stronghold Plus enables Zoetis to offer veterinarians a new topical choice that treats the parasites commonly presenting a threat to cats with one convenient monthly dose,” said Dr. Catherine Knupp, Executive Vice President and President, Research and Development at Zoetis. “For the first time, we have combined our new, versatile parasiticide sarolaner with the active ingredient in Stronghold, selamectin, resulting in the first approval of sarolaner for use in cats. We see sarolaner as a promising platform for future product lines and lifecycle innovations and are pleased with the positive data that sarolaner and its combination continue to generate in studies.” The market for companion animal parasitic medicines was valued at more than $4.2 billion in 2015, with a compound annual growth rate of about 5% over the previous five years, according to Vetnosis1. Domenico Otranto, Professor of Parasitology at The University of Bari in Italy, who recently reviewed the product data of Stronghold Plus, said: “A number of laboratory and field studies show the efficacy of the single spot-on application of Stronghold Plus for at least one month. Veterinarians in the European Union will now have a very effective option for the treatment and control of four prominent species of ticks commonly found on cats while maintaining proven efficacy against fleas, GI worms, heartworms, ear mites and lice. Ultimately, pet owners and practitioners have a new tool for improving the health and welfare of cats.” Dr. Michael Stegemann, Senior Director of Veterinary Research and Development at Zoetis, said: “Stronghold Plus was entirely discovered and developed by Zoetis scientists. It provides fast, sustained coverage from the fleas and ticks most often found on cats. The combined action of sarolaner and selamectin allows Stronghold Plus to kill four species of ticks, and it lengthens the duration of protection against fleas to five full weeks with no drop in efficacy at the end of the dosing period -- all without sacrificing protection from other important internal and external feline parasites. We’re excited to be able to bring this innovation to veterinarians across the European Union.” About Stronghold Plus product efficacy and safety: The active substances in Stronghold Plus are selamectin and sarolaner, a new combination of parasiticides. Selamectin has adulticidal, ovicidal and larvicidal activity against fleas (Ctenocephalides spp). Selamectin is also active against ear mites, lice, gastrointestinal nematodes and prevents heartworm disease through its efficacy against Dirofilaria immitis larvae. Sarolaner is a new acaricide and insecticide belonging to the isoxazoline class: it is efficacious against ticks, fleas and mites. The most common side effects of Stronghold Plus are mild and transient pruritus at the application site. Mild to moderate alopecia at the application site, erythema and drooling have been uncommonly observed. For more information about Stronghold Plus, click here. Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2015, the company generated annual revenue of $4.8 billion with approximately 9,000 employees. For more information, visit www.zoetis.com. Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to business plans or prospects, expectations regarding products and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.


NEW YORK, February 27, 2017 /PRNewswire/ -- This morning's research directs the attention of Stock-Callers.com to the following Generic Drugs stocks: Zoetis Inc. (NYSE: ZTS), Mallinckrodt PLC (NYSE: MNK), Akorn Inc. (NASDAQ: AKRX), and MYOS RENS Technology Inc. (NASDAQ: MYOS). These...


Hu S.X.,Zoetis Inc.
Journal of Veterinary Pharmacology and Therapeutics | Year: 2015

Swine is not only an important species in veterinary medicine research but also a popular animal model for human drug discovery. It is valuable to understand the impact of pig age on abundance and activity of porcine hepatic cytochrome P450 (CYP450). Liver microsomes were prepared from Camborough-29 intact male pigs at the age of 1 day and 2 weeks and the castrated male pigs at the age of 5, 10, and 20 weeks. Hepatic CYP450 content in the liver microsomes was measured using a UV/visible spectroscopic method. The activities of CYP450s were evaluated by metabolism of phenacetin, coumarin, tolbutamide, bufuralol, chlorzoxazone, and midazolam. The porcine hepatic CYP450 content increased with age with a plateau between age 2 and 5 weeks. Activities of all CYP450 enzymes increased with age of pigs too. The bufuralol 1'-hydroxylase showed the highest hepatic activities compared with other CYP enzymes at all ages of pigs. The average activities at the age of 20 weeks were about five times higher than those at the age of 5 weeks for most of the CYP enzymes. With compensation of the ratio of liver to body weights, the overall CYP450 metabolism capability of the pigs may be peaked around ages of 10 to 20 weeks. Those findings suggest that metabolism can be significantly different in growing phase of pigs and that the age may be an important factor in porcine medicine evaluation and pig model development. © 2014 John Wiley & Sons Ltd.


News Article | February 16, 2017
Site: www.businesswire.com

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) ha anunciado que la Comisión Europea ha concedido a la empresa la licencia para Stronghold® Plus (selamectina/sarolaner), una combinación tópica de pasasiticidas para el tratamiento de garrapatas, pulgas, ácaros de oídos, piojos y nematodos gastrointestinales y previene la dirofilariasis en gatos. El comunicado en el idioma original, es la versión oficial y autorizada del mismo. La traducción es solamente un medio de ayuda y deberá ser c


News Article | February 16, 2017
Site: www.businesswire.com

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) ha annunciato in data odierna di avere ottenuto l'autorizzazione della Commissione Europea per Stronghold® Plus (selamectina/sarolaner), un parassiticida di associazione topico per il trattamento di zecche, pulci, acari dell'orecchio, pidocchi e nematodi gastrointestinali e la prevenzione della filariosi nei gatti.

Loading Zoetis Inc. collaborators
Loading Zoetis Inc. collaborators